Company News

Welcome to the Company News room where you can find the latest regulatory news and press releases from our parent company, Open Orphan plc.

31.03.22 Characterisation Study results in Nature Medicine
25.03.22 £5m RSV human challenge study contract win
08.03.22 Trading Update and screening facilities expansion
24.02.22 CEO Appointment
22.02.22 FDA Breakthrough Designation for Big Pharma RSV candidate
17.02.22 Positive results from RSV Human Challenge Study
14.02.22 Launch of STRiVE project
02.02.22 World’s first COVID-19 Characterisation Study
20.01.22 Malaria Human Challenge Model Launched
21.12.21 £5m Influenza human challenge study contract win
10.12.21 $13.4m Influenza HCS contract win
06.12.21 Positive results from Flu Human Challenge Study
17.11.21 £5.1M RSV Contract
15.11.21 £1.5m Contract renewal for Venn Life Sciences
13.10.21 Directorate Change
20.09.21 £5.7m Influenza human challenge study contract win
20.09.21 Half-year Report
07.09.21 Positive results from RSV Human Challenge Study
24.08.21 £8.1m Asthma Human Challenge Study Contract Win
09.08.21 Malaria Human Challenge Model
29.07.21 DNDi Phase II trial support
14.07.21 Directors’ Dealings
14.07.21 AIM Schedule 1 update by Poolbeg Pharma plc
14.07.21 New Contract win for Open Orphan’s Breda office
14.07.21 COVID-19 Human Challenge Programme update
17.06.21 Open Orphan Final Results to 31 December 2020
17.06.21 Poolbeg Pharma Demerger Update
10.05.21 £3m COVID challenge virus manufacturing contract
13.04.21 Potential demerger of certain non-core assets
26.03.21 £7.5m Human Challenge Study Contract
25.03.21 COVID-19 Human Challenge Programme update
11.03.21 Journal for Clinical Studies article publication
09.03.21 New contract win with Oxford BioTherapeutics
17.02.21 Ethics approval – COVID-19 Human Challenge Study
03.02.21 New challenge study quarantine clinic
01.02.21 Contract extension with Carna Biosciences
21.01.21 Article published in Drug Discovery Today
20.01.21 Expansion of volunteer recruitment centres
11.01.21 First volunteer dosed in COVID-19 clinical trial
06.01.21 Contract renewal with top-3 pharmaceutical client
23.12.20 Successful completion of toxicology study
22.12.20 Contract renewal with top-3 pharmaceutical client
14.12.20 MHRA approval for nasal COVID-19 vaccine trial
07.12.20 Venn Life Sciences contract wins
24.11.20 Directors Change
19.11.20 Little-known Irish pharma firm Open Orphan is among best performing on stock exchange on Covid-19 work
19.11.20 Open Orphan subsidiary takes lead role on guidelines for human challenge agents
17.11.20 The ethics of deliberately infecting volunteers with Covid-19 to test vaccines
14.11.20 Irish company to develop world’s first human challenge trial for Covid-19
14.11.20 Coronavirus vaccine: ‘By next summer, Covid will be close to a bad memory’
06.11.20 Open Orphan announces £2.5m influenza challenge study contract
05.11.20 New £2.5m Influenza Challenge Study Contract Win
02.11.20 Business Person of the Month October 2020: Cathal Friel, executive chairman of Open Orphan
31.10.20 Open Orphan signs new contract with German pharma firm
25.10.20 Boss of Open Orphan volunteers for Covid-19 drug trial
20.10.20 Open Orphan/hVIVO Signs Contract with UK Government for the Development of a COVID-19 Human Challenge Study Model
30.09.20 Interim Results for 6 months ended 30 June 2020
28.09.20 New £4.3m Challenge Study Contract Win
24.09.20 Statement re price movement and press speculation
22.09.20 New Contract Win
07.09.20 hVIVO present at 2020 ERS International Congress
10.08.20 Major New Contract Win with Top 3 Pharma Company
04.08.20 New Contract Win with Carna Bioscience (“Carna”)
28.07.20 Contract for COVID-19 Vaccine Trial
15.07.20 Option to Acquire CHIMagents Limited
07.07.20 Additional Laboratory Services Contracts Signed
24.06.20 Results for the year ended 31 December 2019
15.06.20 Positive Phase I results published in The Lancet
11.06.20 Major New Contract Signed
04.06.20 Press Launch of hVIVO COVID Clear Test
22.05.20 Results of Fundraising
22.05.20 Proposed Fundraising to raise up to £12 million
22.05.20 Offer
18.05.20 Update on antibody test and share price movement
11.05.20 New COVID-19 Antibody Testing Partnership
04.05.20 Major New Contract and Directorate Change
23.04.20 Testing of anti-viral for treating COVID-19
16.03.20 Publication of positive results in journal
10.03.20 Publication of Positive Results in Journal
09.03.20 Coronavirus Challenge Study Model
09.03.20 Completion of Compulsory Acquisition of Shares
06.03.20 New Contract
27.02.20 Appointment of new Director
26.02.20 Result of Rule 15 Offer and Total Voting Rights
20.02.20 Appointment of Chair of Advisory Board
31.01.20 Results of Placing and Subscription
31.01.20 Proposed Placing to raise a minimum of £5 million
28.01.20 Compulsory Acquisition of Remaining hVIVO Shares
23.01.20 Update on Placing
20.01.20 Completion of Merger with hVIVO and ReAdmission
17.01.20 Offer Wholly Unconditional
14.01.20 Second Closing of the Offer